EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
Operator: Good morning. My name is Kevin and I will be your conference operator today.
Eyepoint Pharmaceuticals Inc. (EYPT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.79 | 2,567 | 9,967 | 2024-08-20 | Filing | ||
| $7.95 | 5,000 | 13,150 | 2024-08-21 | Filing | ||
| $7.98 | 12,500 | 16,500 | 2024-08-19 | Filing | ||
| $7.88 | 3,173 | 97,635 | 2024-08-16 | Filing | ||
| $12.36 | 207,153 | 8,325,000 | 2024-05-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 11,625 | 1,850 | 2024-07-12 | Filing | ||
| $10.30 | 11,625 | 3,700 | 2024-06-03 | Filing | ||
| $12.65 | 11,625 | 5,550 | 2024-05-14 | Filing | ||
| $28.49 | 209 | 37,962 | 2024-02-02 | Filing | ||
| $25.77 | 33,665 | 36,505 | 2024-01-26 | Filing |
Institutional Investors' Holdings
News See All
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Call Transcript
Operator: Good morning. My name is Leeway and I will be your conference operator today.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2023 Earnings Call Transcript
Operator: Good morning. My name is [indiscernible] and I will be your conference operator today.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2023 Earnings Call Transcript
Operator: Good morning. My name is Desean, and I will be your conference operator today.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2022 Earnings Call Transcript
Operator: Good day and welcome to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Were Hedge Funds Right About EyePoint Pharmaceuticals, Inc. (EYPT)?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Where Do Hedge Funds Stand On EyePoint Pharmaceuticals, Inc. (EYPT)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Should You Buy EyePoint Pharmaceuticals, Inc. (EYPT)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
EyePoint Pharmaceuticals, Inc. (EYPT): Hedge Fund Sentiment Unchanged
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
Hedge Funds Have Never Been This Bullish On EyePoint Pharmaceuticals, Inc. (EYPT)
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research.